RxDoctor Payments Data

Daniel Oleary, MD

Internal Medicine · Leominster, MANPI 1447346531

Payments from drug & device makers

$410in general payments, 2019–2025

Across 10 payments — averaging $41.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$294
  • Novartis$40
  • Novo Nordisk$30
  • Alkermes, Inc.$25
  • GSK$21

What the payments were for

  • Food & beverage$410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Inari Medical, Inc.5$294
Novartis2$40
Novo Nordisk1$30
Alkermes, Inc.1$25
GSK1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$410 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$327,567
Medicare patients
768
Services billed
2,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban348$324,871
JardianceEmpagliflozin113$158,813
TrulicityDulaglutide60$81,837
XareltoRivaroxaban53$55,889
OzempicSemaglutide28$36,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$25,526
OxycontinOxycodone Hcl13$24,535
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate41$18,994
JanuviaSitagliptin Phosphate12$17,599
Atorvastatin Calcium954$16,464
Breo ElliptaFluticasone/Vilanterol27$16,373
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$13,005
Rosuvastatin Calcium377$12,407
Losartan Potassium761$12,334
Levothyroxine Sodium759$10,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$21$41,90053 claims
Novo NordiskOzempic$30$36,16828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Leominster

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →